Leveraging Synthetic Biology and Gut-on-a-Chip Systems to Study Gut Metabolite-Host Interactions: A Case Study in H2s | AIChE

Leveraging Synthetic Biology and Gut-on-a-Chip Systems to Study Gut Metabolite-Host Interactions: A Case Study in H2s

Authors 

Woolston, B., Northeastern University
Koppes, R., Northeastern University
Lunger, A., Northeastern University
Sharma, A., Northeastern University
Koppes, A., Northeastern University
Microbial metabolism in the human gut is increasingly linked with a range of host diseases. Hydrogen sulfide (H2S) is a gaseous microbial metabolite whose role in gut diseases is debated, with contradictory results stemming from experimental difficulties associated with accurate dosing and measuring H2S, and the use of model systems that do not accurately represent the human gut environment. Here, we engineered E. coli to titrate H2S across the physiological range in a gut microphysiological system (chip) supportive of the co-culture of microbes and host cells. The chip was engineered to maintain H2S gas tension and enabled visualization of co-culture in real-time with confocal microscopy. Engineered strains colonized the chip and were metabolically active for two days, during which they produced H2S across a sixteen-fold range and induced changes in host gene expression and metabolism in an H2S concentration-dependent manner. These results validate a platform for studying the mechanisms underlying microbe-host interactions.

These findings motivated the development of microbes capable of sequestering or producing intestinal H2S from different sulfur sources found in the human intestine. First, we engineered a synthetic pathway that converts H2S to glutathione. The strain consumed H2S at a rate of 1 mM H2S/hr-OD600, approximately 10-fold higher than wild type. Next, we engineered a synthetic pathway to convert glutathione to H2S which can produce 0.3 mM H2S/hr-OD600 compared to no H2S production in the wild type. These engineered microbes may be used to modify the intestinal metabolome to drive changes in human disease pathology.